CA2456601A1 - Oral dosage form comprising a therapeutic agent and an adverse-effect agent - Google Patents
Oral dosage form comprising a therapeutic agent and an adverse-effect agent Download PDFInfo
- Publication number
- CA2456601A1 CA2456601A1 CA002456601A CA2456601A CA2456601A1 CA 2456601 A1 CA2456601 A1 CA 2456601A1 CA 002456601 A CA002456601 A CA 002456601A CA 2456601 A CA2456601 A CA 2456601A CA 2456601 A1 CA2456601 A1 CA 2456601A1
- Authority
- CA
- Canada
- Prior art keywords
- dosage form
- oral dosage
- agents
- composition
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Abstract
The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent. The adverse-effect agent is covered with a coating that is substantially insoluble in the gastrointestinal tract. In one embodiment, the adverse-effect agent is coated with an outer base-soluble layer and an inner acid-soluble layer. The therapeutic agent can be uncoated or can be coated with a coating having an outer acid-soluble layer and an inner base-soluble layer. The dosage form discourages administration of the therapeutic agent by other than oral administration.
Claims (79)
1. An oral dosage form comprising a first composition and a second composition, wherein the first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent, wherein the second composition is coated with an inner acid-soluble layer and an outer base-soluble layer.
2. The oral dosage form of claim 1, wherein the first composition and the second composition are in the form of powders, granules, or beads contained within a capsule.
3. The oral dosage form of claim 1, wherein the first composition and the second composition are in the form of granules or a powder dispersed in a pharmaceutically acceptable matrix.
4. The oral dosage form of claim 1 in the form of a two-layer tablet having a first layer comprising the first composition and a second layer comprising the second composition.
5. The oral dosage form of claim 4, wherein the two-layer tablet is further coated with a coating that dissolves in the stomach.
6. The oral dosage form of claim 1, wherein the adverse-effect agent is an antagonist of the therapeutic agent.
7. The oral dosage form of claim 1, wherein the adverse-effect agent is an emetic.
8. The oral dosage form of claim 1, wherein the acid-soluble layer is soluble at a pH value of less than about 5.0 and substantially insoluble at a pH value of greater than about 5.5.
9. The oral dosage form of claim l, wherein the base-soluble layer is soluble at a pH value of greater than about 5.5 but substantially insoluble at a pH value of less than about 5Ø
10. The oral dosage form of claim 1, wherein the acid-soluble layer comprises a cationic polymer with dimethylaminoethyl ammonium functionalities.
11. The oral dosage form of claim 1, wherein the base-soluble layer comprises an anionic polymer of methacrylic acid or a methacrylate with carboxylic acid functionalities.
12. The oral dosage form of claim 1, wherein the first composition is a controlled-release dosage form.
13. The oral dosage form of claim 12, wherein the first composition is coated with a sustained-release coating.
14. The oral dosage form of claim 13, wherein the sustained-release coating is selected from the group consisting of a wax, fatty alcohol, shellac, zero, hydrogenated vegetable oil, water insoluble cellulose, polymers of acrylic acid, polymers of methacrylic acid, copolymers of acrylic acid and methacrylic acid, and mixtures thereof.
15. The oral dosage form of claim 12, wherein the first composition is dispersed in a controlled-release matrix.
16. The oral dosage form of claim 1, wherein the therapeutic agent is selected from a group consisting of analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, anti-bacterial agents, anti-viral agents, anti-coagulants, anti-depressants, anti-diabetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-hypertensive agents, anti-malarials, anti-migraine agents, anti-muscarinic agents, anti-neoplastic agents, erectile dysfunction improvement agents, immunosuppressants, anti-protozoal agents, anti-thyroid agents, anxiolytic agents, sedatives, hypnotics, neuroleptics, ~i-Blockers, cardiac ionotropic agents, corticosteroids, diuretics, anti-parkinsonian agents, gastrointestinal agents, histamine receptor antagonists, keratolytics, lipid regulating agents, anti-anginal agents, cox-2-inhibitors, leukotriene inhibitors, macrolides, muscle relaxants, nutritional agents, opioid analgesics, protease inhibitors, sex hormones, stimulants, muscle relaxants, anti-osteoporosis agents, anti-obesity agents, cognition enhancers, anti-urinary incontinence agents, nutritional oils, 5 anti-benign prostate hypertrophy agents, essential fatty acids, non-essential fatty acids, and mixtures thereof.
17. The oral dosage form of claim 1, wherein the therapeutic agent is an agent having a potential for abuse.
18. The oral dosage form of claim 17, wherein the therapeutic agent is an opioid, benzodiazepine, barbiturate, or a stimulant.
19. The oral dosage form of claim 18, wherein the therapeutic agent is an opioid and the adverse-effect agent is an opioid antagonist.
20. The oral dosage form of claim 19, wherein the opioid is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl, hydrocodone, hydromorphone, hydromorphodone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, paregoric, pentazocine, phenadoxone, phendimetrazine, phendimetrazone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, propylhexedrine, sufentanil, tilidine, tramadol, pharmaceutically acceptable salts thereof, and mixtures thereof.
21. The oral dosage form of claim 20, wherein the opioid is selected from the group consisting of hydrocodone, morphine, hydromorphone, oxycodone, codeine, levorphanol, meperidine, methadone, oxymorphone, buprenorphine, fentanyl and derivatives thereof, dipipanone, heroin, tramadol, etorphine, dihydroetorphine, butorphanol, levorphanol, pharmaceutically acceptable salts thereof, and mixtures thereof.
22. The oral dosage form of claim 21, wherein the opioid is oxycodone or hydrocodone.
23. The oral dosage form of claim 19, wherein the adverse-effect agent is selected from the group consisting of naloxone, naltrexone, nalmefene, cyclazacine, and levallorphan.
24. The oral dosage form of claim 23, wherein the adverse-effect agent is naloxone or naltrexone.
25. The oral dosage form of claim 18, wherein the therapeutic agent is a benzodiazepine and the adverse-effect agent is a benzodiazepine antagonist.
26. The oral dosage form of claim 25, wherein the benzodiazepine is selected from the group consisting of alprazolam, bromazepam, chlordiazepoxied, clorazepate, diazepam, estazolam, flurazepan, halazepam, ketazolam, lorazepam, nitrazepam, oxazepam, prazepam, quazepam, temazepam, triazolam, pharmaceutically acceptable salts thereof, and mixtures thereof .
27. The oral dosage form of claim 25, wherein the benzodiazepine antagonist is flumazenil.
28. The oral dosage form of claim 18, wherein the therapeutic agent is a barbiturate and the adverse-effect agent is a barbiturate antagonist.
29. The oral dosage form of claim 28, wherein the barbiturate is selected from the group consisting of amobarbital, aprobarbotal, butabarbital, butalbital, methohexital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital, pharmaceutically acceptable salts thereof, and mixtures thereof.
30. The oral dosage form of claim 28, wherein the barbiturate antagonist is a stimulant.
31. The oral dosage form of claim 18, wherein the therapeutic agent is a stimulant and the adverse-effect agent is an a stimulant antagonist.
32. The oral dosage form of claim 31, wherein the stimulant is selected from the group consisting of amphetamine, amphetamine and dextroamphetamine resin complex, dextroamphetamine, methamphetamine, methylphenidate, a pharmaceutically acceptable salt thereof, and mixtures thereof.
33. The oral dosage form of claim 31, wherein the stimulant antagonist is a benzodiazepine.
34. The oral dosage form of claim 17, wherein the therapeutic agent is selected from a group consisting of dronabinol, glutethimide, methylphenidate, nabilone, anabolic steroids, methylprylon, ethchlorovynol, ethinamate, fenfluramine, meprobamate, pemoline, levomethadyl, benzphetamine, chlorphentermine, diethylpropion, phentermine, mebutamate, chlortermine, phenylacetone, dronabinol, nabilone, benphetamine, chloral hydrate, ethclorovynol, paraldehyde, midazolam, detropropoxyphene, pharmaceutically acceptable salts thereof, and mixtures thereof.
35. The oral dosage form of claim 1, wherein the therapeutic agent is selected from the group consisting of 5-ASA, steroids, laxatives, octreotide, cisapride, anticholinergics, calcium channel Mockers, DNA for delivery to the cells of the colon, glucosamine, thromboxane Az synthetase inhibitor, SHT3-antagonists, antibodies against infectious bacteria, antiviral agents, heparins, insulin, calcitonins, human growth hormone, growth hormone releasing hormon, interferons, somatostatin and analogues thereof, erythropoietin, granulocyte colony stimulating factor, parathyroid hormone, luteinising hormone releasing hormone and analogues thereof, atrial natriuretic factor, vasopressin, desmopressin, calcitonin gene related peptide, and analgesics.
36. The oral dosage form of claim 1, wherein the ratio of therapeutic agent to adverse-effect agent is from about 1:1 to 50:1.
37. An oral dosage form comprising a first composition and a second composition, wherein the first composition comprises an effective amount of a therapeutic agent and is coated with an inner base-soluble layer and an outer acid-soluble layer and the second composition comprises an effective amount of an adverse-effect agent and is coated with an inner acid-soluble layer and an outer base-soluble layer.
38. The oral dosage form of claim 37, wherein the first composition and the second composition are in the form of powders, granules, or beads contained within a capsule.
39. The oral dosage form of claim 37, wherein the first composition and the second composition are in the form of granules or a powder dispersed in a pharmaceutically acceptable matrix.
40. The oral dosage form of claim 37 in the form of a two-layer tablet having a first layer comprising the first composition and a second layer comprising the second composition.
41. The oral dosage form of claim 40, wherein the two-layer tablet is further coated with a coating that dissolves in the stomach.
42. The oral dosage form of claim 37 in the form of a tablet comprising a core coated with an inner-base soluble layer and an outer acid soluble layer, wherein the core comprises the second composition coated with an inner acid-soluble layer and an outer base-soluble layer dispersed within the therapeutic agent.
43. The oral dosage form of claim 37 in the form of a tablet comprising a core of the second composition coated with an inner acid-soluble layer, an outer base-soluble layer, a coating of the first composition, an inner-base-soluble layer, and an outer acid-soluble layer.
44. The oral dosage form of claim 37, wherein the adverse-effect agent is an antagonist of the therapeutic agent.
45. The oral dosage form of claim 37, wherein the adverse-effect agent is laxative.
46. The oral dosage form of claim 37, wherein each acid-soluble layer is soluble at a pH value of less than about 5.0 and substantially insoluble at a pH value of greater than about 5.5.
47. The oral dosage form of claim 37, wherein each base-soluble layer is soluble at a pH value of greater than about 5.5 but substantially insoluble at a pH value of less than about 5Ø
48. The oral dosage form of claim 37, wherein each acid-soluble layer comprises a cationic polymer with dimethylaminoethyl ammonium functionalities.
49. The oral dosage form of claim 37, wherein each base-soluble layer comprises an anionic polymer of methacrylic acid or a methacrylate with carboxylic acid functionalities.
50. The oral dosage form of claim 37, wherein the first composition is a controlled-release dosage form.
51. The oral dosage form of claim S0, wherein the first composition is coated with an inner-most sustained-release coating.
52. The oral dosage form of claim 51, wherein the sustained-release coating is selected from the group consisting of a wax, fatty alcohol, shellac, zero, hydrogenated vegetable oil, water insoluble cellulose, polymers of acrylic acid, polymers of methacrylic acid, copolymers of acrylic acid and methacrylic acid, and mixtures thereof.
53. The oral dosage form of claim S0, wherein the first composition is dispersed in a controlled-release matrix.
54. The oral dosage form of claim 37, wherein the therapeutic agent is selected from a group consisting of analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, anti-bacterial agents, anti-viral agents, anti-coagulants, anti-depressants, anti-diabetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-hypertensive agents, anti-malarials, anti-migraine agents, anti-muscarinic agents, anti-neoplastic agents, erectile dysfunction improvement agents, immunosuppressants, anti-protozoal agents, anti-thyroid agents, anxiolytic agents, sedatives, hypnotics, neuroleptics, .beta.-Blockers, cardiac ionotropic agents, corticosteroids, diuretics, anti-parkinsonian agents, gastrointestinal agents, histamine receptor antagonists, keratolytics, lipid regulating agents, anti-anginal agents, cox-2-inhibitors, leukotriene inhibitors, macrolides, muscle relaxants, nutritional agents, opioid analgesics, protease inhibitors, sex hormones, stimulants, muscle relaxants, anti-osteoporosis agents, anti-obesity agents, cognition enhancers, anti-urinary incontinence agents, nutritional oils, anti-benign prostate hypertrophy agents, essential fatty acids, non-essential fatty acids, and mixtures thereof.
55. The oral dosage form of claim 37, wherein the therapeutic agent is an agent having a potential for abuse.
56. The oral dosage form of claim 55, wherein the therapeutic agent is an opioid, benzodiazepine, barbiturate, or a stimulant.
57. The oral dosage form of claim 56, wherein the therapeutic agent is an opioid and the adverse-effect agent is an opioid antagonist.
58. The oral dosage form of claim 57, wherein the opioid is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl, hydrocodone, hydromorphone, hydromorphodone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, paregoric, pentazocine, phenadoxone, phendimetrazine, phendimetrazone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, propylhexedrine, sufentanil, tilidine, tramadol, pharmaceutically acceptable salts thereof, and mixtures thereof.
59. The oral dosage form of claim 58, wherein the opioid selected from the group consisting of hydrocodone, morphine, hydromorphone, oxycodone, codeine, levorphanol, meperidine, methadone, oxyrnorphone, buprenorphine, fentanyl and derivatives thereof, dipipanone, heroin, tramadol, etorphine, dihydroetorphine, butorphanol, levorphanol, pharmaceutically acceptable salts thereof, and mixtures thereof.
60. The oral dosage form of claim 59, wherein the opioid is oxycodone or hydrocodone.
61. The oral dosage form of claim 57, wherein the adverse-effect agent is selected from the group consisting of naloxone, naltrexone, nalmefene, cyclazacine, and levallorphan.
62. The oral dosage form of claim 57, wherein the adverse-effect agent is naloxone or naltrexone.
63. The oral dosage form of claim 56, wherein the therapeutic agent is a benzodiazepine and the adverse-effect agent is a benzodiazepine antagonist.
64. The oral dosage form of claim 63, wherein the benzodiazepine is selected from the group consisting of alprazolam, bromazepam, chlordiazepoxied, clorazepate, diazepam, estazolam, flurazepan, halazepam, ketazolam, lorazepam, nitrazepam, oxazepam, prazepam, quazepam, temazepam, triazolam, pharmaceutically acceptable salts thereof, and mixtures thereof.
65. The oral dosage form of claim 63, wherein the benzodiazepine antagonist is flumazenil.
66. The oral dosage form of claim 56, wherein the therapeutic agent is a barbiturate and the adverse-effect agent is a barbiturate antagonist.
67. The oral dosage form of claim 66, wherein the barbiturate is selected from the group consisting of amobarbital, aprobarbotal, butabarbital, butalbital, methohexital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital, pharmaceutically acceptable salts thereof, and mixture thereof.
68. The oral dosage form of claim 56, wherein the barbiturate antagonist is a stimulant.
69. The oral dosage form of claim 5, wherein the therapeutic agent is a stimulant and the adverse-effect agent is a stimulant antagonist.
70. The oral dosage form of claim 69, wherein the amphetamine is selected from the group consisting of amphetamine, amphetamine and dextroamphetamine resin complex, dextroamphetamine, methamphetamine, methylphenidate, a pharmaceutically acceptable salt thereof, and mixtures thereof.
71. The oral dosage form of claim 69, wherein the stimulant antagonist is a benzodiazepine.
72. The oral dosage form of claim 56, wherein the therapeutic agent is selected from a group consisting of dronabinol, glutethimide, methylphenidate, nabilone, anabolic steroids, methylprylon, ethchlorovynol, ethinamate, fenfluramine, meprobamate, pemoline, levomethadyl, benzphetamine, chlorphentermine, diethylpropion, phentermine, mebutamate, chlortermine, phenylacetone, dronabinol, nabilone, benphetamine, chloral hydrate, ethclorovynol, paraldehyde, midazolam, detropropoxyphene, pharmaceutically acceptable salts thereof, and mixtures thereof.
73. The oral dosage form of claim 37, wherein the therapeutic agent is selected from the group consisting of 5-ASA, steroids, laxatives, octreotide, cisapride, anticholinergics, calcium channel Mockers, DNA for delivery to the cells of the colon, glucosamine, thromboxane A2 synthetase inhibitor, SHT3-antagonists, antibodies against infectious bacteria, antiviral agents, heparins, insulin, calcitonins, human growth hormone, growth hormone releasing hormon, interferons, somatostatin and analogues thereof, erythropoietin, granulocyte colony stimulating factor, parathyroid hormone, luteinising hormone releasing hormone and analogues thereof, atrial natriuretic factor, vasopressin, desmopressin, calcitonin gene related peptide, and analgesics.
74. The oral dosage form of claim 37, wherein the ratio of therapeutic agent to adverse-effect agent is from about 1:1 to 50:1.
75. A method for treating or preventing pain, comprising administering to a patient in need thereof the oral dosage form of claim 1.
76. A method for treating or preventing pain, comprising administering to a patient in need thereof the oral dosage form of claim 37.
77. A method for treating or preventing pain, comprising administering to a patient in need thereof an oral dosage form comprising a first composition and a second composition, wherein:
the first composition comprises an effective amount of a therapeutic agent;
the second composition comprises an effective amount of an adverse-effect agent;
effective amount of the therapeutic agent is released in the patient's small intestine; and less than an effective amount of the adverse-effect agent is released in the patient's gastrointestinal tract.
the first composition comprises an effective amount of a therapeutic agent;
the second composition comprises an effective amount of an adverse-effect agent;
effective amount of the therapeutic agent is released in the patient's small intestine; and less than an effective amount of the adverse-effect agent is released in the patient's gastrointestinal tract.
78. A method for preparing the oral dosage form of claim 1, comprising the step of preparing the oral dosage form as set forth herein.
79. A method for preparing the oral dosage form of claim 37, comprising the step of preparing the oral dosage form as set forth herein.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30979101P | 2001-08-06 | 2001-08-06 | |
US60/309,791 | 2001-08-06 | ||
US10/208,817 | 2002-08-01 | ||
US10/208,817 US20030044458A1 (en) | 2001-08-06 | 2002-08-01 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
PCT/US2002/024889 WO2003013538A1 (en) | 2001-08-06 | 2002-08-05 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2456601A1 true CA2456601A1 (en) | 2003-02-20 |
CA2456601C CA2456601C (en) | 2012-04-24 |
Family
ID=23199688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2456601A Expired - Lifetime CA2456601C (en) | 2001-08-06 | 2002-08-05 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
Country Status (19)
Country | Link |
---|---|
US (3) | US20030044458A1 (en) |
EP (1) | EP1414459B1 (en) |
JP (3) | JP5143995B2 (en) |
KR (2) | KR20090005247A (en) |
AT (1) | ATE450259T1 (en) |
AU (1) | AU2008202531A1 (en) |
BR (1) | BR0211781A (en) |
CA (1) | CA2456601C (en) |
CY (1) | CY1109816T1 (en) |
DE (1) | DE20220838U1 (en) |
DK (1) | DK1414459T3 (en) |
ES (1) | ES2337664T3 (en) |
HK (1) | HK1067524A1 (en) |
HU (1) | HUP0401066A2 (en) |
MX (1) | MXPA04001098A (en) |
PT (1) | PT1414459E (en) |
RU (1) | RU2004106620A (en) |
SI (1) | SI1414459T1 (en) |
WO (1) | WO2003013538A1 (en) |
Families Citing this family (184)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2415876T3 (en) | 1997-12-22 | 2013-07-29 | Euro-Celtique S.A. | Oral pharmaceutical dosage form comprising a combination of an opioid agonist and an opioid antagonist |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
EP1389092B1 (en) * | 2001-05-11 | 2006-11-15 | Endo Pharmaceuticals Inc. | Abuse-resistant opioid dosage form |
EP1387673B1 (en) | 2001-05-11 | 2010-12-29 | Endo Pharmaceuticals Inc. | Abuse-resistant controlled-release opioid dosage form |
US9820982B2 (en) * | 2001-07-06 | 2017-11-21 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US20030129234A1 (en) * | 2001-07-06 | 2003-07-10 | Penwest Pharmaceuticals Company | Methods of making sustained release formulations of oxymorphone |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US20030091635A1 (en) * | 2001-09-26 | 2003-05-15 | Baichwal Anand R. | Opioid formulations having reduced potential for abuse |
EP3241548A1 (en) | 2002-04-05 | 2017-11-08 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
KR101061351B1 (en) | 2002-04-09 | 2011-08-31 | 플라멜 테크놀로지스 | Oral Suspension of Active Ingredient Microcapsules |
US8501232B2 (en) * | 2002-04-23 | 2013-08-06 | Nanotherapeutics, Inc. | Process of forming and modifying particles and compositions produced thereby |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US7771707B2 (en) | 2004-06-12 | 2010-08-10 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
US7815934B2 (en) | 2002-09-20 | 2010-10-19 | Alpharma Pharmaceuticals, Llc | Sequestering subunit and related compositions and methods |
DE10250087A1 (en) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form protected against abuse |
DE10250084A1 (en) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form protected against abuse |
US20050186139A1 (en) * | 2002-10-25 | 2005-08-25 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US7524515B2 (en) * | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
MXPA05011071A (en) * | 2003-04-21 | 2005-12-12 | Euro Celtique Sa | Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same. |
EP2316440A1 (en) * | 2003-04-30 | 2011-05-04 | Purdue Pharma L.P. | Transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer and one fluid communication between the surface of the active agent and the adverse agent |
US8790689B2 (en) * | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
JP2007520202A (en) | 2003-06-20 | 2007-07-26 | ニュートリニア・リミテッド | Method for protecting biologically active compounds and compositions containing same |
US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
PL1842533T3 (en) * | 2003-08-06 | 2013-08-30 | Gruenenthal Gmbh | Dosage form that is secured against misuse |
DE10361596A1 (en) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE102004032051A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
DE102004020220A1 (en) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
EP1660048A4 (en) * | 2003-08-12 | 2009-07-08 | Endo Pharmaceuticals Inc | Method for deterring abuse of opioids by combination with non-release formulation of emetic |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
CA2552677A1 (en) * | 2004-01-13 | 2005-07-28 | Vasogenix Pharmaceuticals, Inc. | Controlled release cgrp delivery composition for cardiovascular and renal indications |
CA2552758A1 (en) * | 2004-01-13 | 2005-08-04 | Vasogenix Pharmaceuticals, Inc. | Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same |
GB0403098D0 (en) * | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
TWI350762B (en) * | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
CN1938004B (en) | 2004-03-30 | 2011-12-21 | 欧洲凯尔特公司 | Tamper resistant dosage form comprising an adsorbent and an adverse agent |
US20050271594A1 (en) * | 2004-06-04 | 2005-12-08 | Groenewoud Pieter J | Abuse resistent pharmaceutical composition |
DK1768650T3 (en) * | 2004-06-04 | 2008-09-29 | Camurus Ab | Liquid storage formulations |
EP1604666A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
DE102004032049A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
DE102004032103A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
CA2580329C (en) | 2004-09-13 | 2015-01-06 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery |
ES2531735T3 (en) * | 2004-10-15 | 2015-03-18 | Supernus Pharmaceuticals, Inc. | Pharmaceutical preparations with lower potential for abuse |
TWI369203B (en) | 2004-11-22 | 2012-08-01 | Euro Celtique Sa | Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol |
US20070231268A1 (en) * | 2004-11-24 | 2007-10-04 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060110327A1 (en) * | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060177380A1 (en) * | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
WO2006058294A2 (en) * | 2004-11-29 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
CN101132772B (en) * | 2005-01-28 | 2012-05-09 | 欧洲凯尔特公司 | Alcohol resistant dosage forms |
DE102005005449A1 (en) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
EP1695700A1 (en) * | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
US20090110633A1 (en) * | 2005-03-14 | 2009-04-30 | Shiladitya Sengupta | Nanocells for Diagnosis and Treatment of Diseases and Disorders |
US7786308B2 (en) * | 2005-03-28 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
US9060950B2 (en) * | 2005-06-13 | 2015-06-23 | Paul H. Rosenberg, Proximate Concepts, LLC. | Emetic embedded capsule |
EP1893183A4 (en) * | 2005-06-13 | 2010-08-18 | Paul Rosenberg | Emetic embedded capsule |
WO2006133733A1 (en) * | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
WO2007013975A2 (en) * | 2005-07-20 | 2007-02-01 | Pharmorx Inc. | Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications |
EP1767247B1 (en) * | 2005-09-26 | 2008-11-26 | Faber-Castell AG | Liquid cosmetic composition for colouring the nails and the skin |
US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
FR2892937B1 (en) * | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING |
CA2629046C (en) | 2005-12-13 | 2014-04-08 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
EP1810678A1 (en) | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Use of morphine and naloxone for drug substitution |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
CN104825397A (en) | 2006-04-03 | 2015-08-12 | 伊萨·奥迪迪 | Controlled release delivery device comprising an organosol coat |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
HUE032156T2 (en) | 2006-06-19 | 2017-09-28 | Alpharma Pharmaceuticals Llc | Pharmaceutical compositions |
KR101230804B1 (en) | 2006-07-21 | 2013-02-08 | 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 | Transmucosal delivery devices with enhanced uptake |
US20080075771A1 (en) * | 2006-07-21 | 2008-03-27 | Vaughn Jason M | Hydrophilic opioid abuse deterrent delivery system using opioid antagonists |
EA015304B1 (en) | 2006-08-03 | 2011-06-30 | Нитек Фарма Аг | Delayed-release glucocorticoid treatment of rheumatoid disease |
CA2659122C (en) * | 2006-08-04 | 2016-08-23 | Ethypharm | Granule and orally disintegrating tablet comprising oxycodone |
WO2008024490A2 (en) * | 2006-08-24 | 2008-02-28 | Theraquest Biosciences, Inc. | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use |
EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
US8187636B2 (en) * | 2006-09-25 | 2012-05-29 | Atlantic Pharmaceuticals, Inc. | Dosage forms for tamper prone therapeutic agents |
DE102007011485A1 (en) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
SI2197429T1 (en) | 2007-09-03 | 2016-09-30 | Nanotherapeutics, Inc. | Particulate compositions for delivery of poorly soluble drugs |
EP2042176A1 (en) * | 2007-09-26 | 2009-04-01 | Euro-Celtique S.A. | Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease |
US8802156B2 (en) * | 2007-11-14 | 2014-08-12 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
BRPI0821732A2 (en) | 2007-12-17 | 2015-06-16 | Labopharm Inc | Controlled release formulations, solid dosage form, and use of controlled release formulation |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
CA3066426A1 (en) * | 2008-01-09 | 2009-07-16 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
JP5774853B2 (en) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Pharmaceutical dosage form |
CA2753844A1 (en) * | 2008-03-05 | 2009-09-11 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
EP2262367A4 (en) * | 2008-03-08 | 2011-04-20 | Theraquest Biosciences Inc | Oral pharmaceutical compositions of buprenorphine and method of use |
EP2273983B1 (en) * | 2008-05-09 | 2016-07-20 | Grünenthal GmbH | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
CA2730211C (en) * | 2008-07-07 | 2016-11-08 | Euro-Celtique S.A. | Use of opioid antagonists for treating urinary retention |
US20100099696A1 (en) * | 2008-10-16 | 2010-04-22 | Anthony Edward Soscia | Tamper resistant oral dosage forms containing an embolizing agent |
WO2010068891A2 (en) * | 2008-12-11 | 2010-06-17 | L'oreal S.A. | Lengthening mascara composition |
ES2414856T3 (en) * | 2008-12-12 | 2013-07-23 | Paladin Labs Inc. | Narcotic drug formulations with decreased addiction potential |
EP2367541B1 (en) | 2008-12-16 | 2014-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
WO2010084188A1 (en) * | 2009-01-26 | 2010-07-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of asthma |
NZ582836A (en) * | 2009-01-30 | 2011-06-30 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage |
MX347106B (en) | 2009-03-10 | 2017-04-12 | Euro-Celtique S A * | Immediate release pharmaceutical compositions comprising oxycodone and naloxone. |
CN102365083A (en) * | 2009-03-18 | 2012-02-29 | 赢创罗姆有限公司 | Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients |
CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
ES2560210T3 (en) | 2009-07-22 | 2016-02-17 | Grünenthal GmbH | Tamper-resistant dosage form for oxidation-sensitive opiates |
JP5667183B2 (en) | 2009-07-22 | 2015-02-12 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Controlled release dosage form with heat melt extrusion |
US20120302590A1 (en) | 2009-08-13 | 2012-11-29 | The General Hospital Corporation | Methods and compositions to prevent addiction |
WO2011041414A1 (en) | 2009-09-30 | 2011-04-07 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
ES2606227T3 (en) * | 2010-02-03 | 2017-03-23 | Grünenthal GmbH | Preparation of a pharmaceutical powder composition by an extruder |
IT1398930B1 (en) * | 2010-03-24 | 2013-03-28 | Molteni & C | PHARMACEUTICAL FORMULATIONS BISTRATO CONTAINING OPPOSING AGONISTS AND ANTAGONISTS. |
GB2479213B (en) * | 2010-04-01 | 2013-07-10 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
KR20130137627A (en) | 2010-09-02 | 2013-12-17 | 그뤼넨탈 게엠베하 | Tamper resistant dosage form comprising an anionic polymer |
RU2604676C2 (en) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Destruction-resistant dosage form containing an inorganic salt |
KR101572336B1 (en) | 2010-12-22 | 2015-11-26 | 퍼듀 퍼머 엘피 | Encased tamper resistant controlled release dosage forms |
CN103327969A (en) | 2010-12-23 | 2013-09-25 | 普渡制药公司 | Tamper resistant solid oral dosage forms |
CA2827336C (en) | 2011-02-23 | 2016-01-26 | Coeruleus Ltd. | Flumazenil complexes, compositions comprising same and uses thereof |
AU2012253667B2 (en) | 2011-05-10 | 2017-06-01 | Theravida, Inc. | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder |
WO2013006643A1 (en) * | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
WO2013017234A1 (en) | 2011-07-29 | 2013-02-07 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
AR087359A1 (en) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | TEST ALTERATION TABLET PROVIDING IMMEDIATE RELEASE OF THE PHARMACO |
PE20141198A1 (en) | 2011-09-19 | 2014-10-05 | Orexo Ab | NEW PHARMACEUTICAL COMPOSITION RESISTANT TO ABUSE FOR THE TREATMENT OF OPIOID DEPENDENCE |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
US9763928B2 (en) * | 2012-02-10 | 2017-09-19 | Niconovum Usa, Inc. | Multi-layer nicotine-containing pharmaceutical composition |
MX356421B (en) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer. |
SG11201405011PA (en) * | 2012-03-02 | 2014-09-26 | Rhodes Pharmaceuticals Lp | Tamper resistant immediate release formulations |
AR092820A1 (en) | 2012-04-17 | 2015-05-06 | Purdue Pharma Lp | SYSTEMS AND METHODS TO TREAT AN ADVERSE ADVERSE PHARMACODYNAMIC RESPONSE, DOSE UNIT, KIT |
ES2692944T3 (en) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Pharmaceutical dosage form resistant to handling and resistant to rapid discharge of the dose |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
EP3326613A1 (en) | 2012-07-26 | 2018-05-30 | Camurus AB | Opioid formulations |
WO2014059512A1 (en) * | 2012-10-15 | 2014-04-24 | Isa Odidi | Oral drug delivery formulations |
RU2018141241A (en) | 2012-11-30 | 2019-01-24 | Экьюра Фармасьютикалз, Инк. | SELF-ADJUSTABLE RELEASE OF PHARMACEUTICAL INGREDIENT |
US8999393B1 (en) * | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
US20150342946A1 (en) | 2013-01-30 | 2015-12-03 | Pharmorx Therapeutics, Inc. | Treatments For Depression And Other Diseases With A Low Dose Agent |
EA201500742A1 (en) | 2013-02-05 | 2015-12-30 | Пердью Фарма Л.П. | PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
EP3003283A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
EA032465B1 (en) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof |
EP3024461B1 (en) | 2013-07-23 | 2020-05-13 | Euro-Celtique S.A. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
JP6539274B2 (en) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | Extruded immediate release abuse deterrent pills |
US9763912B2 (en) | 2013-10-30 | 2017-09-19 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions, methods of use, and methods of treatment |
WO2015078891A1 (en) | 2013-11-26 | 2015-06-04 | Farmaceutici Formenti S.P.A. | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
AU2015237723B2 (en) | 2014-03-26 | 2018-04-26 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release biphasic matrix solid dosage form |
CN106572980A (en) | 2014-05-12 | 2017-04-19 | 格吕伦塔尔有限公司 | Tamper resistant immediate release capsule formulation comprising tapentadol |
EP3148512A1 (en) | 2014-05-26 | 2017-04-05 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
JP6371463B2 (en) | 2014-07-17 | 2018-08-08 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | Immediate release abuse deterrent liquid filler form |
US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
KR20170139158A (en) | 2015-04-24 | 2017-12-18 | 그뤼넨탈 게엠베하 | Immediate release and solvent extraction inhibition modulated dosage form |
US11103581B2 (en) | 2015-08-31 | 2021-08-31 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
US9889120B2 (en) | 2016-01-14 | 2018-02-13 | Vicus Therapeutics, Llc | Combination drug therapies for cancer and methods of making and using them |
AU2016388308B2 (en) | 2016-01-20 | 2022-08-04 | Theravida, Inc. | Methods and compositions for treating hyperhidrosis |
JP2019507181A (en) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ,インコーポレイテッド | Pharmaceutical composition |
US10046032B2 (en) | 2016-03-24 | 2018-08-14 | Nutrinia, Ltd. | Use of insulin for promoting gastric emptying |
US10143687B2 (en) | 2016-04-11 | 2018-12-04 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
US10292977B2 (en) | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
EP3318252A1 (en) * | 2016-11-08 | 2018-05-09 | Alpex Pharma SA | Extended release tablet comprising a weight-loss drug |
US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
WO2019173062A1 (en) | 2018-03-07 | 2019-09-12 | Trucapsol, Llc | Reduced permeability microcapsules |
US11344502B1 (en) | 2018-03-29 | 2022-05-31 | Trucapsol Llc | Vitamin delivery particle |
JP7420797B2 (en) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | Drug delivery methods and systems |
US11794161B1 (en) | 2018-11-21 | 2023-10-24 | Trucapsol, Llc | Reduced permeability microcapsules |
US10758532B2 (en) | 2018-12-11 | 2020-09-01 | Satsuma Pharmaceuticals, Inc. | Compositions, devices, and methods for treating or preventing headaches |
US11571674B1 (en) | 2019-03-28 | 2023-02-07 | Trucapsol Llc | Environmentally biodegradable microcapsules |
US11542392B1 (en) | 2019-04-18 | 2023-01-03 | Trucapsol Llc | Multifunctional particle additive for enhancement of toughness and degradation in biodegradable polymers |
CA3150767A1 (en) * | 2019-08-12 | 2021-02-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pharmaceutical compositions comprising a combination of opioid antagonists |
US11547978B2 (en) | 2020-01-30 | 2023-01-10 | Trucapsol Llc | Environmentally biodegradable microcapsules |
US11878280B2 (en) | 2022-04-19 | 2024-01-23 | Trucapsol Llc | Microcapsules comprising natural materials |
US11904288B1 (en) | 2023-02-13 | 2024-02-20 | Trucapsol Llc | Environmentally biodegradable microcapsules |
Family Cites Families (196)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2770569A (en) | 1952-08-01 | 1956-11-13 | Hoffmann La Roche | Analgesic compositions |
US3173877A (en) * | 1957-09-09 | 1965-03-16 | Wyandotte Chemicals Corp | Detergent compositions comprising inorganic esters of epoxyhydrocarbon polymers |
US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
NL271831A (en) * | 1960-11-29 | |||
US3493657A (en) * | 1961-03-14 | 1970-02-03 | Mozes Juda Lewenstein | Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine |
US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
NL6714885A (en) | 1967-11-02 | 1969-05-06 | ||
US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
US3773955A (en) * | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US3879555A (en) * | 1970-11-16 | 1975-04-22 | Bristol Myers Co | Method of treating drug addicts |
US3676557A (en) | 1971-03-02 | 1972-07-11 | Endo Lab | Long-acting narcotic antagonist formulations |
US3965256A (en) * | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3980766A (en) | 1973-08-13 | 1976-09-14 | West Laboratories, Inc. | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
US3916889A (en) | 1973-09-28 | 1975-11-04 | Sandoz Ag | Patient ventilator apparatus |
US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
US4175119A (en) * | 1978-01-11 | 1979-11-20 | Porter Garry L | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs |
US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
NO154582C (en) * | 1978-10-20 | 1986-11-05 | Ferrosan Ab | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DIPHENYL-DIBUTYLPIPERAZINE CARBOXAMIDS. |
US4285987A (en) | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4237140A (en) | 1979-05-18 | 1980-12-02 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and acetaminophen |
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
IE49324B1 (en) | 1979-12-19 | 1985-09-18 | Euro Celtique Sa | Controlled release compositions |
US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4587118A (en) * | 1981-07-15 | 1986-05-06 | Key Pharmaceuticals, Inc. | Dry sustained release theophylline oral formulation |
US4401672A (en) | 1981-10-13 | 1983-08-30 | Regents Of The University Of Minnesota | Non-addictive narcotic antitussive preparation |
US4608376A (en) | 1981-10-16 | 1986-08-26 | Carolyn McGinnis | Opiate agonists and antagonists |
US4987136A (en) * | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
US4424205A (en) * | 1982-03-18 | 1984-01-03 | The Procter & Gamble Company | Hydroxyphenylacetamides having analgesic and anti-irritant activity |
US4443428A (en) * | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
US4451470A (en) * | 1982-07-06 | 1984-05-29 | E. I. Du Pont De Nemours And Company | Analgesic, antagonist, and/or anorectic 14-fluoromorphinans |
JPS5951223A (en) * | 1982-09-17 | 1984-03-24 | Sumitomo Chem Co Ltd | Pharmaceutical composition |
JPS5951223U (en) | 1982-09-28 | 1984-04-04 | 曙ブレーキ工業株式会社 | Floating caliper type disc brake |
US4803208A (en) * | 1982-09-30 | 1989-02-07 | Sloan-Kettering Institute For Cancer Research | Opiate agonists and antagonists |
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4681897A (en) * | 1984-01-16 | 1987-07-21 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US5266574A (en) * | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
DE3434946A1 (en) * | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | DIARYLACETYLENE, THEIR PRODUCTION AND USE |
US4573995A (en) * | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4806341A (en) * | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
FR2585246A1 (en) * | 1985-07-26 | 1987-01-30 | Cortial | PROCESS FOR OBTAINING SOLID PHARMACEUTICAL FORMS WITH PROLONGED RELEASE |
GB8521350D0 (en) | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
GB2181346B (en) * | 1985-09-11 | 1989-10-04 | Nat Res Dev | Pharmaceutical compositions and medical uses of dioxopiperidine derivatives |
US4889860A (en) | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4760069A (en) | 1985-09-23 | 1988-07-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4730048A (en) * | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4719215A (en) * | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB8613689D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
ATE107857T1 (en) * | 1986-06-10 | 1994-07-15 | Euro Celtique Sa | COMPOSITION WITH CONTROLLED RELEASE OF DIHYDROCODEINE. |
US4798725A (en) * | 1986-06-16 | 1989-01-17 | Norwich Eaton Pharmaceuticals, Inc. | Sustained release capsule |
US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4861598A (en) | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US5356900A (en) | 1986-10-07 | 1994-10-18 | Bernard Bihari | Method of treating chronic herpes virus infections using an opiate receptor antagonist |
GB8626098D0 (en) * | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US4806543A (en) * | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
GB8628728D0 (en) | 1986-12-02 | 1987-01-07 | Euro Celtique Sa | Spheroids |
GB8705083D0 (en) | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
GB8728294D0 (en) * | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
DE3812567A1 (en) | 1988-04-15 | 1989-10-26 | Basf Ag | METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES |
US4873076A (en) | 1988-04-29 | 1989-10-10 | Baker Cummins Pharmaceuticals, Inc. | Method of safely providing anesthesia or conscious sedation |
GB8813064D0 (en) * | 1988-06-02 | 1988-07-06 | Euro Celtique Sa | Controlled release dosage forms having defined water content |
US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
US4939149A (en) * | 1988-10-24 | 1990-07-03 | The United States Of America As Represented By The Department Of Health And Human Services | Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization |
US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
US5026556A (en) * | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
US5403868A (en) * | 1988-12-23 | 1995-04-04 | Sandoz Ltd. | Capsaicin derivatives |
US5102887A (en) * | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
US5096715A (en) * | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
US5240711A (en) | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
KR950005865B1 (en) | 1990-04-23 | 1995-06-02 | 데이진 가부시끼가이샤 | Plaster |
US5086058A (en) * | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
FR2669336B1 (en) | 1990-11-20 | 1993-01-22 | Adir | NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
HU208633B (en) * | 1991-02-04 | 1993-12-28 | Alkaloida Vegyeszeti Gyar | Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression |
US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
KR100221695B1 (en) * | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | Pharmaceutical spheroid formulation |
HU219332B (en) | 1991-09-06 | 2001-03-28 | Mcneilab Inc | Synergetic medicaments containing trans-(+)-2-[(dimethylamino)-methyl]-1-(3-methoxiphenyl)-cyclohexanol and acetaminophen |
US5215758A (en) * | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5225440A (en) | 1991-09-13 | 1993-07-06 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase |
AU2679892A (en) | 1991-09-18 | 1993-04-27 | Agp Surface Control Systems, Inc. | One coat protective system for a surface |
US5226331A (en) | 1991-10-03 | 1993-07-13 | General Electric Company | Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
GB9203689D0 (en) * | 1992-02-20 | 1992-04-08 | Euro Celtique Sa | Pharmaceutical composition |
GB9204354D0 (en) | 1992-02-28 | 1992-04-08 | Biokine Tech Ltd | Compounds for medicinal use |
EP0647137B1 (en) * | 1992-06-22 | 2008-08-13 | The Regents Of The University Of California | Glycine receptor antagonists and the use thereof |
US5352680A (en) | 1992-07-15 | 1994-10-04 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
US5256669A (en) | 1992-08-07 | 1993-10-26 | Aminotek Sciences, Inc. | Methods and compositions for treating acute or chronic pain and drug addiction |
US5324351A (en) * | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
US5633259A (en) * | 1992-09-21 | 1997-05-27 | United Biomedical, Inc. | Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction |
US5580876A (en) | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5869097A (en) * | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
US5604260A (en) * | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
JPH0710745Y2 (en) | 1993-01-27 | 1995-03-15 | 吉範 安田 | Nursing sheets |
US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5585348A (en) | 1993-02-10 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia |
CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
US5409944A (en) * | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
NZ260408A (en) | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
JPH0710745A (en) * | 1993-06-22 | 1995-01-13 | Tanabe Seiyaku Co Ltd | Oral preparation for release-starting time control type intestinal delivery |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
IL110014A (en) | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
GB9319568D0 (en) | 1993-09-22 | 1993-11-10 | Euro Celtique Sa | Pharmaceutical compositions and usages |
US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US6210714B1 (en) * | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
KR100354702B1 (en) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | Manufacturing method and sustained release composition of pharmaceutical composition |
US5891471A (en) * | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
US5834477A (en) | 1993-12-08 | 1998-11-10 | The United States Of America As Represented By The Secretary Of The Army | Opiate analgesic formulation with improved safety |
US5376662A (en) | 1993-12-08 | 1994-12-27 | Ockert; David M. | Method of attenuating nerve injury induced pain |
US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
DE69535432T2 (en) * | 1994-04-22 | 2007-12-06 | Astellas Pharma Inc. | Colon-specific drug delivery system |
US6077533A (en) | 1994-05-25 | 2000-06-20 | Purdue Pharma L.P. | Powder-layered oral dosage forms |
US5411745A (en) * | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
US5460826A (en) | 1994-06-27 | 1995-10-24 | Alza Corporation | Morphine therapy |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) * | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5593994A (en) * | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
GB9422154D0 (en) * | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
ATE300308T1 (en) * | 1994-12-12 | 2005-08-15 | Omeros Corp | IRGINATION SOLUTION AND THE USE THEREOF FOR THE PERIOPERATIVE INHIBITION OF PAIN, INFLAMMATION AND SPASMS IN A WOUND |
GB9426102D0 (en) * | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5578725A (en) | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
US5604253A (en) * | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5510368A (en) * | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
US5639780A (en) * | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5762963A (en) * | 1995-06-07 | 1998-06-09 | Emory University | Method and compositions for controlling oral and pharyngeal pain using capsaicinoids |
HUP9700322A3 (en) | 1995-06-09 | 2001-03-28 | Euro Celtique Sa | Formulations and methods for providing prolonged local anesthesia |
JP3185206B2 (en) * | 1995-07-20 | 2001-07-09 | 田辺製薬株式会社 | Lower digestive tract release coated capsule formulation |
SG80553A1 (en) | 1995-07-20 | 2001-05-22 | Tanabe Seiyaku Co | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
GB9517883D0 (en) | 1995-09-01 | 1995-11-01 | Euro Celtique Sa | Improved pharmaceutical ion exchange resin composition |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
US5811126A (en) | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
US5998434A (en) | 1995-12-06 | 1999-12-07 | Eli Lilly And Company | Composition for treating pain |
DK0914097T3 (en) * | 1996-03-12 | 2002-04-29 | Alza Corp | Composition and dosage form comprising opioid antagonist |
US6103258A (en) | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
US5780479A (en) | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
JPH10338634A (en) * | 1997-04-11 | 1998-12-22 | Grelan Pharmaceut Co Ltd | Medicinal composition |
WO1999001111A1 (en) | 1997-07-02 | 1999-01-14 | Euro-Celtique, S.A. | Stabilized sustained release tramadol formulations |
US5891919A (en) * | 1997-09-19 | 1999-04-06 | Burlington Bio-Medical & Scientific Corp. | Denatonium capsaicinate and methods of producing the same |
US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
TR200001828T2 (en) | 1997-12-22 | 2000-11-21 | Euro-Celtique, S.A. | A method to prevent abuse of opioid dosage forms. |
ES2415876T3 (en) * | 1997-12-22 | 2013-07-29 | Euro-Celtique S.A. | Oral pharmaceutical dosage form comprising a combination of an opioid agonist and an opioid antagonist |
RU2236847C2 (en) | 1998-11-02 | 2004-09-27 | Илан Корпорейшн, Плк. | Composition as multiple particles with modified release |
JP2002535353A (en) * | 1999-01-29 | 2002-10-22 | ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク | Pharmaceutical composition |
GB9905558D0 (en) | 1999-03-11 | 1999-05-05 | Reckitt & Colmann Prod Ltd | Improvements in or relating to organic compositions |
US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
CN101703777B (en) * | 2000-02-08 | 2012-11-28 | 欧罗赛铁克股份有限公司 | Tamper-resistant oral opioid agonist formulations |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
EP1389092B1 (en) * | 2001-05-11 | 2006-11-15 | Endo Pharmaceuticals Inc. | Abuse-resistant opioid dosage form |
US20030064122A1 (en) * | 2001-05-23 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse resistant pharmaceutical composition containing capsaicin |
WO2003002100A1 (en) * | 2001-06-26 | 2003-01-09 | Farrell John J | Tamper-proof narcotic delivery system |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US7144587B2 (en) | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
DE10250084A1 (en) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form protected against abuse |
US8906413B2 (en) | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
US7201920B2 (en) * | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
US7867511B2 (en) | 2004-01-23 | 2011-01-11 | Travanti Pharma Inc. | Abuse potential reduction in abusable substance dosage form |
-
2002
- 2002-08-01 US US10/208,817 patent/US20030044458A1/en not_active Abandoned
- 2002-08-05 RU RU2004106620/15A patent/RU2004106620A/en not_active Application Discontinuation
- 2002-08-05 HU HU0401066A patent/HUP0401066A2/en unknown
- 2002-08-05 JP JP2003518547A patent/JP5143995B2/en not_active Expired - Lifetime
- 2002-08-05 CA CA2456601A patent/CA2456601C/en not_active Expired - Lifetime
- 2002-08-05 DE DE20220838U patent/DE20220838U1/en not_active Expired - Lifetime
- 2002-08-05 AT AT02761250T patent/ATE450259T1/en active
- 2002-08-05 ES ES02761250T patent/ES2337664T3/en not_active Expired - Lifetime
- 2002-08-05 MX MXPA04001098A patent/MXPA04001098A/en active IP Right Grant
- 2002-08-05 PT PT02761250T patent/PT1414459E/en unknown
- 2002-08-05 KR KR1020087030854A patent/KR20090005247A/en not_active Application Discontinuation
- 2002-08-05 KR KR1020047001854A patent/KR100893895B1/en active IP Right Grant
- 2002-08-05 EP EP02761250A patent/EP1414459B1/en not_active Expired - Lifetime
- 2002-08-05 SI SI200230884T patent/SI1414459T1/en unknown
- 2002-08-05 WO PCT/US2002/024889 patent/WO2003013538A1/en active Application Filing
- 2002-08-05 DK DK02761250.6T patent/DK1414459T3/en active
- 2002-08-05 BR BR0211781-9A patent/BR0211781A/en not_active Application Discontinuation
-
2004
- 2004-09-23 US US10/948,575 patent/US7384653B2/en not_active Ceased
- 2004-11-03 HK HK04108654.6A patent/HK1067524A1/en not_active IP Right Cessation
-
2008
- 2008-06-06 AU AU2008202531A patent/AU2008202531A1/en not_active Abandoned
- 2008-11-19 JP JP2008295477A patent/JP5485538B2/en not_active Expired - Fee Related
-
2010
- 2010-02-12 CY CY20101100149T patent/CY1109816T1/en unknown
-
2013
- 2013-05-13 JP JP2013101285A patent/JP2013189447A/en active Pending
- 2013-10-28 US US13/923,362 patent/USRE45822E1/en active Active
Also Published As
Publication number | Publication date |
---|---|
DK1414459T3 (en) | 2010-04-12 |
PT1414459E (en) | 2010-03-03 |
ES2337664T3 (en) | 2010-04-28 |
JP5143995B2 (en) | 2013-02-13 |
HUP0401066A2 (en) | 2004-08-30 |
US20050063909A1 (en) | 2005-03-24 |
USRE45822E1 (en) | 2015-12-22 |
WO2003013538A1 (en) | 2003-02-20 |
BR0211781A (en) | 2004-07-27 |
HK1067524A1 (en) | 2005-04-15 |
CA2456601C (en) | 2012-04-24 |
DE20220838U1 (en) | 2004-05-19 |
US7384653B2 (en) | 2008-06-10 |
JP5485538B2 (en) | 2014-05-07 |
JP2009132711A (en) | 2009-06-18 |
EP1414459A1 (en) | 2004-05-06 |
ATE450259T1 (en) | 2009-12-15 |
KR100893895B1 (en) | 2009-04-20 |
SI1414459T1 (en) | 2010-04-30 |
KR20090005247A (en) | 2009-01-12 |
JP2005520783A (en) | 2005-07-14 |
RU2004106620A (en) | 2005-04-10 |
JP2013189447A (en) | 2013-09-26 |
KR20040043181A (en) | 2004-05-22 |
US20030044458A1 (en) | 2003-03-06 |
AU2008202531A1 (en) | 2008-07-03 |
MXPA04001098A (en) | 2004-05-20 |
EP1414459B1 (en) | 2009-12-02 |
CY1109816T1 (en) | 2014-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2456601A1 (en) | Oral dosage form comprising a therapeutic agent and an adverse-effect agent | |
US10039720B2 (en) | Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same | |
EP1691892B1 (en) | Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same | |
HRP20151189T1 (en) | Tamper-resistant products for opioid delivery | |
US10441547B2 (en) | Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same | |
CA2557839A1 (en) | Tamper resistant dosage form comprising an adsorbent and an adverse agent | |
CA2640339A1 (en) | Tamper resistant opioid dosage forms | |
CA2652981A1 (en) | Robust sustained release formulations | |
JP2006524261A5 (en) | ||
US20070185145A1 (en) | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same | |
CA2654700A1 (en) | Transdermal patch | |
CA2486075A1 (en) | Abuse-resistant opioid solid dosage form | |
CA2661573A1 (en) | Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic | |
HRP20210973T1 (en) | Abuse resistant pharmaceutical compositions | |
SG191872A1 (en) | Pharmaceutical composition comprising opioid agonist and sequestered antagonist | |
NZ589627A (en) | Pharmaceutical compositions comprising an opioid and a 4-(2-furanyl)thiazole compound for suppressing undesirable effects of opioids | |
HRP20141001T1 (en) | Pharmaceutical spheroids | |
CA2446639A1 (en) | Composition for the prevention of addiction in pain management | |
US20170157055A1 (en) | Pharmaceutical abuse deterrent composition | |
AU2011205217A1 (en) | Oral dosage form comprising a therapeutic agent and an adverse-effect agent | |
AU2002326529A1 (en) | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20220805 |